Takeda says Phase III trial for its Ninlaro was effective in extending progression free survival

Japanese drug major Takeda Pharmaceutical (TSE: 4502) said late-stage trial for its Ninlaro (ixazomib) was effective in extending progression free survival (PFS) in patients with relapsed and/or refractory multiple myeloma.

Dr Andy Plump, Takeda’s chief medical and scientific officer, said: “The data presented at ASH this year are the first major output from the comprehensive ixazomib clinical trial program, Tourmaline, demonstrating Takeda’s ongoing commitment to providing effective and convenient treatment options for patients with multiple myeloma The breadth and depth of the Tourmaline program allows us to gather important data across a broad range of patients that live with multiple myeloma and to expand on the efficacy and safety profile of our oral proteasome inhibitor, ixazomib. We will continue this and other important clinical trials and look forward to sharing results over the next few years.”

Phase III trial data for ixazomib data will be featured in 18 presentations at this year’s American Society of Hematology (ASH) meeting, including an oral presentation on Phase II data from an investigational study evaluating the all-oral combination of ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in newly diagnosed multiple myeloma patients.